Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 55. More products

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Telmisartan (02432897), Telmisartan (02432900). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

TELMISARTAN

All products: general benefit

Other products in the same Health Canada class (C09CA) — coverage varies; not interchangeable

  • Candesartan cilexetil (Atacand): general benefit
  • Irbesartan (Avapro): general benefit, Not a benefit
  • Losartan (Cozaar): general benefit
  • Olmesartan medoxomil (Olmetec): general benefit
  • Valsartan (Diovan): general benefit, Not a benefit
  • Eprosartan (Teveten): general benefit

Ach-Telmisartan · DIN 02407485 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Telmisartan · DIN 02407485 Manufacturer: Accord Healthcare Inc.; listing date 2014-09-25 Health Canada: Marketed since 2023-04-14 · brand ACH-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 40 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89217 · Verify on the e-Formulary ↗ (DIN 02407485)

Source record
DIN 02407485: Ach-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800237; group id 352; item number 0812; lccId None; manufacturer id ACH Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02407485 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89217
Interchangeable products
Apo-Telmisartan · DIN 02420082 · $0.2161 Auro-Telmisartan · DIN 02453568 · $0.2161 Jamp Telmisartan · DIN 02386755 · $0.2161 Micardis · DIN 02240769 · $0.2161 Mint-Telmisartan · DIN 02486369 · $0.2161 NRA-Telmisartan · DIN 02503794 · $0.2161 PMS-Telmisartan · DIN 02499622 · $0.2161 Sandoz Telmisartan · DIN 02375958 · $0.2161 Telmisartan · DIN 02388944 · $0.2161 Telmisartan · DIN 02390345 · $0.2161 Teva-Telmisartan · DIN 02320177 · $0.2161
Shortage status: resolved shortage (ended 2025-12-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02407485
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Telmisartan · DIN 02453568 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Telmisartan · DIN 02453568 Manufacturer: Auro Pharma Inc.; listing date 2016-12-22 Health Canada: Marketed since 2016-04-08 · brand AURO-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 40 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94012 · Verify on the e-Formulary ↗ (DIN 02453568)

Source record
DIN 02453568: Auro-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800237; group id 352; item number 0812; lccId None; manufacturer id AUR Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02453568 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94012
Interchangeable products
Ach-Telmisartan · DIN 02407485 · $0.2161 Apo-Telmisartan · DIN 02420082 · $0.2161 Jamp Telmisartan · DIN 02386755 · $0.2161 Micardis · DIN 02240769 · $0.2161 Mint-Telmisartan · DIN 02486369 · $0.2161 NRA-Telmisartan · DIN 02503794 · $0.2161 PMS-Telmisartan · DIN 02499622 · $0.2161 Sandoz Telmisartan · DIN 02375958 · $0.2161 Telmisartan · DIN 02388944 · $0.2161 Telmisartan · DIN 02390345 · $0.2161 Teva-Telmisartan · DIN 02320177 · $0.2161
Shortage status: resolved shortage (ended 2023-11-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02453568
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Telmisartan · DIN 02386755 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Telmisartan · DIN 02386755 Manufacturer: Jamp Pharma Corporation; listing date 2021-02-26 Health Canada: Marketed since 2020-12-29 · brand JAMP TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 40 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87235 · Verify on the e-Formulary ↗ (DIN 02386755)

Source record
DIN 02386755: Jamp Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800237; group id 352; item number 0812; lccId None; manufacturer id JPC Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386755 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87235
Interchangeable products
Ach-Telmisartan · DIN 02407485 · $0.2161 Apo-Telmisartan · DIN 02420082 · $0.2161 Auro-Telmisartan · DIN 02453568 · $0.2161 Micardis · DIN 02240769 · $0.2161 Mint-Telmisartan · DIN 02486369 · $0.2161 NRA-Telmisartan · DIN 02503794 · $0.2161 PMS-Telmisartan · DIN 02499622 · $0.2161 Sandoz Telmisartan · DIN 02375958 · $0.2161 Telmisartan · DIN 02388944 · $0.2161 Telmisartan · DIN 02390345 · $0.2161 Teva-Telmisartan · DIN 02320177 · $0.2161
Shortage status: resolved shortage (ended 2025-03-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02386755
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Micardis · DIN 02240769 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Micardis · DIN 02240769 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2000-04-17 Health Canada: Marketed since 1999-09-01 · brand MICARDIS 40MG TAB · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 40 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64358 · Verify on the e-Formulary ↗ (DIN 02240769)

Source record
DIN 02240769: Micardis Raw flags: chronicUseMed=Y, sec3=Y Item: 240800237; group id 352; item number 0812; lccId None; manufacturer id BOE Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.4498; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240769 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64358
Interchangeable products
Ach-Telmisartan · DIN 02407485 · $0.2161 Apo-Telmisartan · DIN 02420082 · $0.2161 Auro-Telmisartan · DIN 02453568 · $0.2161 Jamp Telmisartan · DIN 02386755 · $0.2161 Mint-Telmisartan · DIN 02486369 · $0.2161 NRA-Telmisartan · DIN 02503794 · $0.2161 PMS-Telmisartan · DIN 02499622 · $0.2161 Sandoz Telmisartan · DIN 02375958 · $0.2161 Telmisartan · DIN 02388944 · $0.2161 Telmisartan · DIN 02390345 · $0.2161 Teva-Telmisartan · DIN 02320177 · $0.2161
Shortage status: resolved shortage (ended 2020-07-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240769
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Telmisartan · DIN 02486369 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Telmisartan · DIN 02486369 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-07-31 Health Canada: Marketed since 2020-04-16 · brand MINT-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 40 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97657 · Verify on the e-Formulary ↗ (DIN 02486369)

Source record
DIN 02486369: Mint-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800237; group id 352; item number 0812; lccId None; manufacturer id MIN Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02486369 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97657
Interchangeable products
Ach-Telmisartan · DIN 02407485 · $0.2161 Apo-Telmisartan · DIN 02420082 · $0.2161 Auro-Telmisartan · DIN 02453568 · $0.2161 Jamp Telmisartan · DIN 02386755 · $0.2161 Micardis · DIN 02240769 · $0.2161 NRA-Telmisartan · DIN 02503794 · $0.2161 PMS-Telmisartan · DIN 02499622 · $0.2161 Sandoz Telmisartan · DIN 02375958 · $0.2161 Telmisartan · DIN 02388944 · $0.2161 Telmisartan · DIN 02390345 · $0.2161 Teva-Telmisartan · DIN 02320177 · $0.2161
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02486369
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Telmisartan · DIN 02503794 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Telmisartan · DIN 02503794 Manufacturer: Nora Pharma; listing date 2022-02-28 Health Canada: Marketed since 2024-10-16 · brand NRA-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 40 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99323 · Verify on the e-Formulary ↗ (DIN 02503794)

Source record
DIN 02503794: NRA-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800237; group id 352; item number 0812; lccId None; manufacturer id NRA Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02503794 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99323
Interchangeable products
Ach-Telmisartan · DIN 02407485 · $0.2161 Apo-Telmisartan · DIN 02420082 · $0.2161 Auro-Telmisartan · DIN 02453568 · $0.2161 Jamp Telmisartan · DIN 02386755 · $0.2161 Micardis · DIN 02240769 · $0.2161 Mint-Telmisartan · DIN 02486369 · $0.2161 PMS-Telmisartan · DIN 02499622 · $0.2161 Sandoz Telmisartan · DIN 02375958 · $0.2161 Telmisartan · DIN 02388944 · $0.2161 Telmisartan · DIN 02390345 · $0.2161 Teva-Telmisartan · DIN 02320177 · $0.2161
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02503794
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Telmisartan · DIN 02499622 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Telmisartan · DIN 02499622 Manufacturer: Pharmascience Inc.; listing date 2021-05-31 Health Canada: Marketed since 2021-03-25 · brand PMS-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 40 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98935 · Verify on the e-Formulary ↗ (DIN 02499622)

Source record
DIN 02499622: PMS-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800237; group id 352; item number 0812; lccId None; manufacturer id PMS Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02499622 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98935
Interchangeable products
Ach-Telmisartan · DIN 02407485 · $0.2161 Apo-Telmisartan · DIN 02420082 · $0.2161 Auro-Telmisartan · DIN 02453568 · $0.2161 Jamp Telmisartan · DIN 02386755 · $0.2161 Micardis · DIN 02240769 · $0.2161 Mint-Telmisartan · DIN 02486369 · $0.2161 NRA-Telmisartan · DIN 02503794 · $0.2161 Sandoz Telmisartan · DIN 02375958 · $0.2161 Telmisartan · DIN 02388944 · $0.2161 Telmisartan · DIN 02390345 · $0.2161 Teva-Telmisartan · DIN 02320177 · $0.2161
Shortage status: resolved shortage (ended 2024-11-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02499622
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Telmisartan · DIN 02375958 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Telmisartan · DIN 02375958 Manufacturer: Sandoz Canada Inc.; listing date 2012-02-29 Health Canada: Marketed since 2012-01-04 · brand SANDOZ TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 40 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86141 · Verify on the e-Formulary ↗ (DIN 02375958)

Source record
DIN 02375958: Sandoz Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800237; group id 352; item number 0812; lccId None; manufacturer id SDZ Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02375958 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86141
Interchangeable products
Ach-Telmisartan · DIN 02407485 · $0.2161 Apo-Telmisartan · DIN 02420082 · $0.2161 Auro-Telmisartan · DIN 02453568 · $0.2161 Jamp Telmisartan · DIN 02386755 · $0.2161 Micardis · DIN 02240769 · $0.2161 Mint-Telmisartan · DIN 02486369 · $0.2161 NRA-Telmisartan · DIN 02503794 · $0.2161 PMS-Telmisartan · DIN 02499622 · $0.2161 Telmisartan · DIN 02388944 · $0.2161 Telmisartan · DIN 02390345 · $0.2161 Teva-Telmisartan · DIN 02320177 · $0.2161
Shortage status: resolved shortage (ended 2025-03-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02375958
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Telmisartan · DIN 02388944 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Telmisartan · DIN 02388944 Manufacturer: Sanis Health Inc.; listing date 2020-09-30 Health Canada: Marketed since 2023-08-29 · brand TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 40 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87447 · Verify on the e-Formulary ↗ (DIN 02388944)

Source record
DIN 02388944: Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800237; group id 352; item number 0812; lccId None; manufacturer id SAI Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388944 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87447
Interchangeable products
Ach-Telmisartan · DIN 02407485 · $0.2161 Apo-Telmisartan · DIN 02420082 · $0.2161 Auro-Telmisartan · DIN 02453568 · $0.2161 Jamp Telmisartan · DIN 02386755 · $0.2161 Micardis · DIN 02240769 · $0.2161 Mint-Telmisartan · DIN 02486369 · $0.2161 NRA-Telmisartan · DIN 02503794 · $0.2161 PMS-Telmisartan · DIN 02499622 · $0.2161 Sandoz Telmisartan · DIN 02375958 · $0.2161 Telmisartan · DIN 02390345 · $0.2161 Teva-Telmisartan · DIN 02320177 · $0.2161
Shortage status: resolved shortage (ended 2024-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388944
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Telmisartan · DIN 02390345 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Telmisartan · DIN 02390345 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2021-05-31 Health Canada: Marketed since 2025-07-23 · brand TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 40 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87579 · Verify on the e-Formulary ↗ (DIN 02390345)

Source record
DIN 02390345: Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800237; group id 352; item number 0812; lccId None; manufacturer id SIV Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390345 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87579
Interchangeable products
Ach-Telmisartan · DIN 02407485 · $0.2161 Apo-Telmisartan · DIN 02420082 · $0.2161 Auro-Telmisartan · DIN 02453568 · $0.2161 Jamp Telmisartan · DIN 02386755 · $0.2161 Micardis · DIN 02240769 · $0.2161 Mint-Telmisartan · DIN 02486369 · $0.2161 NRA-Telmisartan · DIN 02503794 · $0.2161 PMS-Telmisartan · DIN 02499622 · $0.2161 Sandoz Telmisartan · DIN 02375958 · $0.2161 Telmisartan · DIN 02388944 · $0.2161 Teva-Telmisartan · DIN 02320177 · $0.2161
Shortage status: resolved shortage (ended 2024-04-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02390345
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Telmisartan · DIN 02320177 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Telmisartan · DIN 02320177 Manufacturer: Teva Canada Limited; listing date 2012-03-26 Health Canada: Marketed since 2012-01-09 · brand TEVA-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 40 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80562 · Verify on the e-Formulary ↗ (DIN 02320177)

Source record
DIN 02320177: Teva-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800237; group id 352; item number 0812; lccId None; manufacturer id TEV Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02320177 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80562
Interchangeable products
Ach-Telmisartan · DIN 02407485 · $0.2161 Apo-Telmisartan · DIN 02420082 · $0.2161 Auro-Telmisartan · DIN 02453568 · $0.2161 Jamp Telmisartan · DIN 02386755 · $0.2161 Micardis · DIN 02240769 · $0.2161 Mint-Telmisartan · DIN 02486369 · $0.2161 NRA-Telmisartan · DIN 02503794 · $0.2161 PMS-Telmisartan · DIN 02499622 · $0.2161 Sandoz Telmisartan · DIN 02375958 · $0.2161 Telmisartan · DIN 02388944 · $0.2161 Telmisartan · DIN 02390345 · $0.2161
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02320177
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Telmisartan · DIN 02407493 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Telmisartan · DIN 02407493 Manufacturer: Accord Healthcare Inc.; listing date 2014-09-25 Health Canada: Marketed since 2022-08-03 · brand ACH-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 80 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89218 · Verify on the e-Formulary ↗ (DIN 02407493)

Source record
DIN 02407493: Ach-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800238; group id 352; item number 0813; lccId None; manufacturer id ACH Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02407493 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89218
Interchangeable products
Apo-Telmisartan · DIN 02420090 · $0.2161 Auro-Telmisartan · DIN 02453576 · $0.2161 Co Telmisartan · DIN 02393255 · $0.2161 Jamp Telmisartan · DIN 02386763 · $0.2161 Micardis · DIN 02240770 · $0.2161 Mint-Telmisartan · DIN 02486377 · $0.2161 NRA-Telmisartan · DIN 02503808 · $0.2161 PMS-Telmisartan · DIN 02499630 · $0.2161 Sandoz Telmisartan · DIN 02375966 · $0.2161 Telmisartan · DIN 02388952 · $0.2161 Telmisartan · DIN 02390353 · $0.2161 Teva-Telmisartan · DIN 02320185 · $0.2161
Shortage status: resolved shortage (ended 2023-12-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02407493
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Telmisartan · DIN 02453576 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Telmisartan · DIN 02453576 Manufacturer: Auro Pharma Inc.; listing date 2016-12-22 Health Canada: Marketed since 2016-04-08 · brand AURO-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 80 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94013 · Verify on the e-Formulary ↗ (DIN 02453576)

Source record
DIN 02453576: Auro-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800238; group id 352; item number 0813; lccId None; manufacturer id AUR Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02453576 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94013
Interchangeable products
Ach-Telmisartan · DIN 02407493 · $0.2161 Apo-Telmisartan · DIN 02420090 · $0.2161 Co Telmisartan · DIN 02393255 · $0.2161 Jamp Telmisartan · DIN 02386763 · $0.2161 Micardis · DIN 02240770 · $0.2161 Mint-Telmisartan · DIN 02486377 · $0.2161 NRA-Telmisartan · DIN 02503808 · $0.2161 PMS-Telmisartan · DIN 02499630 · $0.2161 Sandoz Telmisartan · DIN 02375966 · $0.2161 Telmisartan · DIN 02388952 · $0.2161 Telmisartan · DIN 02390353 · $0.2161 Teva-Telmisartan · DIN 02320185 · $0.2161
Shortage status: resolved shortage (ended 2024-03-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02453576
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Telmisartan · DIN 02386763 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Telmisartan · DIN 02386763 Manufacturer: Jamp Pharma Corporation; listing date 2021-02-26 Health Canada: Marketed since 2020-12-29 · brand JAMP TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 80 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87236 · Verify on the e-Formulary ↗ (DIN 02386763)

Source record
DIN 02386763: Jamp Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800238; group id 352; item number 0813; lccId None; manufacturer id JPC Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386763 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87236
Interchangeable products
Ach-Telmisartan · DIN 02407493 · $0.2161 Apo-Telmisartan · DIN 02420090 · $0.2161 Auro-Telmisartan · DIN 02453576 · $0.2161 Co Telmisartan · DIN 02393255 · $0.2161 Micardis · DIN 02240770 · $0.2161 Mint-Telmisartan · DIN 02486377 · $0.2161 NRA-Telmisartan · DIN 02503808 · $0.2161 PMS-Telmisartan · DIN 02499630 · $0.2161 Sandoz Telmisartan · DIN 02375966 · $0.2161 Telmisartan · DIN 02388952 · $0.2161 Telmisartan · DIN 02390353 · $0.2161 Teva-Telmisartan · DIN 02320185 · $0.2161
Shortage status: resolved shortage (ended 2025-10-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02386763
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Micardis · DIN 02240770 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Micardis · DIN 02240770 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2000-04-17 Health Canada: Marketed since 1999-09-01 · brand MICARDIS 80MG TAB · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 80 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64359 · Verify on the e-Formulary ↗ (DIN 02240770)

Source record
DIN 02240770: Micardis Raw flags: chronicUseMed=Y, sec3=Y Item: 240800238; group id 352; item number 0813; lccId None; manufacturer id BOE Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.4498; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240770 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64359
Interchangeable products
Ach-Telmisartan · DIN 02407493 · $0.2161 Apo-Telmisartan · DIN 02420090 · $0.2161 Auro-Telmisartan · DIN 02453576 · $0.2161 Co Telmisartan · DIN 02393255 · $0.2161 Jamp Telmisartan · DIN 02386763 · $0.2161 Mint-Telmisartan · DIN 02486377 · $0.2161 NRA-Telmisartan · DIN 02503808 · $0.2161 PMS-Telmisartan · DIN 02499630 · $0.2161 Sandoz Telmisartan · DIN 02375966 · $0.2161 Telmisartan · DIN 02388952 · $0.2161 Telmisartan · DIN 02390353 · $0.2161 Teva-Telmisartan · DIN 02320185 · $0.2161
Shortage status: resolved shortage (ended 2020-07-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240770
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Telmisartan · DIN 02486377 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Telmisartan · DIN 02486377 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-07-31 Health Canada: Marketed since 2020-03-18 · brand MINT-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 80 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97658 · Verify on the e-Formulary ↗ (DIN 02486377)

Source record
DIN 02486377: Mint-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800238; group id 352; item number 0813; lccId None; manufacturer id MIN Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02486377 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97658
Interchangeable products
Ach-Telmisartan · DIN 02407493 · $0.2161 Apo-Telmisartan · DIN 02420090 · $0.2161 Auro-Telmisartan · DIN 02453576 · $0.2161 Co Telmisartan · DIN 02393255 · $0.2161 Jamp Telmisartan · DIN 02386763 · $0.2161 Micardis · DIN 02240770 · $0.2161 NRA-Telmisartan · DIN 02503808 · $0.2161 PMS-Telmisartan · DIN 02499630 · $0.2161 Sandoz Telmisartan · DIN 02375966 · $0.2161 Telmisartan · DIN 02388952 · $0.2161 Telmisartan · DIN 02390353 · $0.2161 Teva-Telmisartan · DIN 02320185 · $0.2161
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02486377
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Telmisartan · DIN 02503808 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Telmisartan · DIN 02503808 Manufacturer: Nora Pharma; listing date 2022-02-28 Health Canada: Marketed since 2024-10-16 · brand NRA-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 80 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99324 · Verify on the e-Formulary ↗ (DIN 02503808)

Source record
DIN 02503808: NRA-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800238; group id 352; item number 0813; lccId None; manufacturer id NRA Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02503808 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99324
Interchangeable products
Ach-Telmisartan · DIN 02407493 · $0.2161 Apo-Telmisartan · DIN 02420090 · $0.2161 Auro-Telmisartan · DIN 02453576 · $0.2161 Co Telmisartan · DIN 02393255 · $0.2161 Jamp Telmisartan · DIN 02386763 · $0.2161 Micardis · DIN 02240770 · $0.2161 Mint-Telmisartan · DIN 02486377 · $0.2161 PMS-Telmisartan · DIN 02499630 · $0.2161 Sandoz Telmisartan · DIN 02375966 · $0.2161 Telmisartan · DIN 02388952 · $0.2161 Telmisartan · DIN 02390353 · $0.2161 Teva-Telmisartan · DIN 02320185 · $0.2161
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02503808
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Telmisartan · DIN 02499630 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Telmisartan · DIN 02499630 Manufacturer: Pharmascience Inc.; listing date 2021-05-31 Health Canada: Marketed since 2021-03-25 · brand PMS-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 80 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98936 · Verify on the e-Formulary ↗ (DIN 02499630)

Source record
DIN 02499630: PMS-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800238; group id 352; item number 0813; lccId None; manufacturer id PMS Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02499630 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98936
Interchangeable products
Ach-Telmisartan · DIN 02407493 · $0.2161 Apo-Telmisartan · DIN 02420090 · $0.2161 Auro-Telmisartan · DIN 02453576 · $0.2161 Co Telmisartan · DIN 02393255 · $0.2161 Jamp Telmisartan · DIN 02386763 · $0.2161 Micardis · DIN 02240770 · $0.2161 Mint-Telmisartan · DIN 02486377 · $0.2161 NRA-Telmisartan · DIN 02503808 · $0.2161 Sandoz Telmisartan · DIN 02375966 · $0.2161 Telmisartan · DIN 02388952 · $0.2161 Telmisartan · DIN 02390353 · $0.2161 Teva-Telmisartan · DIN 02320185 · $0.2161
Shortage status: resolved shortage (ended 2024-11-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02499630
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Telmisartan · DIN 02375966 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Telmisartan · DIN 02375966 Manufacturer: Sandoz Canada Inc.; listing date 2012-02-29 Health Canada: Marketed since 2012-01-04 · brand SANDOZ TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 80 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86142 · Verify on the e-Formulary ↗ (DIN 02375966)

Source record
DIN 02375966: Sandoz Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800238; group id 352; item number 0813; lccId None; manufacturer id SDZ Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02375966 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86142
Interchangeable products
Ach-Telmisartan · DIN 02407493 · $0.2161 Apo-Telmisartan · DIN 02420090 · $0.2161 Auro-Telmisartan · DIN 02453576 · $0.2161 Co Telmisartan · DIN 02393255 · $0.2161 Jamp Telmisartan · DIN 02386763 · $0.2161 Micardis · DIN 02240770 · $0.2161 Mint-Telmisartan · DIN 02486377 · $0.2161 NRA-Telmisartan · DIN 02503808 · $0.2161 PMS-Telmisartan · DIN 02499630 · $0.2161 Telmisartan · DIN 02388952 · $0.2161 Telmisartan · DIN 02390353 · $0.2161 Teva-Telmisartan · DIN 02320185 · $0.2161
Shortage status: resolved shortage (ended 2025-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02375966
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Telmisartan · DIN 02388952 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Telmisartan · DIN 02388952 Manufacturer: Sanis Health Inc.; listing date 2020-09-30 Health Canada: Marketed since 2023-08-29 · brand TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 80 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87448 · Verify on the e-Formulary ↗ (DIN 02388952)

Source record
DIN 02388952: Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800238; group id 352; item number 0813; lccId None; manufacturer id SAI Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388952 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87448
Interchangeable products
Ach-Telmisartan · DIN 02407493 · $0.2161 Apo-Telmisartan · DIN 02420090 · $0.2161 Auro-Telmisartan · DIN 02453576 · $0.2161 Co Telmisartan · DIN 02393255 · $0.2161 Jamp Telmisartan · DIN 02386763 · $0.2161 Micardis · DIN 02240770 · $0.2161 Mint-Telmisartan · DIN 02486377 · $0.2161 NRA-Telmisartan · DIN 02503808 · $0.2161 PMS-Telmisartan · DIN 02499630 · $0.2161 Sandoz Telmisartan · DIN 02375966 · $0.2161 Telmisartan · DIN 02390353 · $0.2161 Teva-Telmisartan · DIN 02320185 · $0.2161
Shortage status: resolved shortage (ended 2020-03-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388952
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Telmisartan · DIN 02390353 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Telmisartan · DIN 02390353 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2021-05-31 Health Canada: Marketed since 2025-07-23 · brand TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 80 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87580 · Verify on the e-Formulary ↗ (DIN 02390353)

Source record
DIN 02390353: Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800238; group id 352; item number 0813; lccId None; manufacturer id SIV Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390353 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87580
Interchangeable products
Ach-Telmisartan · DIN 02407493 · $0.2161 Apo-Telmisartan · DIN 02420090 · $0.2161 Auro-Telmisartan · DIN 02453576 · $0.2161 Co Telmisartan · DIN 02393255 · $0.2161 Jamp Telmisartan · DIN 02386763 · $0.2161 Micardis · DIN 02240770 · $0.2161 Mint-Telmisartan · DIN 02486377 · $0.2161 NRA-Telmisartan · DIN 02503808 · $0.2161 PMS-Telmisartan · DIN 02499630 · $0.2161 Sandoz Telmisartan · DIN 02375966 · $0.2161 Telmisartan · DIN 02388952 · $0.2161 Teva-Telmisartan · DIN 02320185 · $0.2161
Shortage status: resolved shortage (ended 2025-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02390353
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Telmisartan · DIN 02320185 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Telmisartan · DIN 02320185 Manufacturer: Teva Canada Limited; listing date 2012-03-26 Health Canada: Marketed since 2012-01-09 · brand TEVA-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 80 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80563 · Verify on the e-Formulary ↗ (DIN 02320185)

Source record
DIN 02320185: Teva-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800238; group id 352; item number 0813; lccId None; manufacturer id TEV Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02320185 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80563
Interchangeable products
Ach-Telmisartan · DIN 02407493 · $0.2161 Apo-Telmisartan · DIN 02420090 · $0.2161 Auro-Telmisartan · DIN 02453576 · $0.2161 Co Telmisartan · DIN 02393255 · $0.2161 Jamp Telmisartan · DIN 02386763 · $0.2161 Micardis · DIN 02240770 · $0.2161 Mint-Telmisartan · DIN 02486377 · $0.2161 NRA-Telmisartan · DIN 02503808 · $0.2161 PMS-Telmisartan · DIN 02499630 · $0.2161 Sandoz Telmisartan · DIN 02375966 · $0.2161 Telmisartan · DIN 02388952 · $0.2161 Telmisartan · DIN 02390353 · $0.2161
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02320185
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Telmisartan · DIN 02420082 · 40mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued 2025-04-17 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Telmisartan · DIN 02420082 Manufacturer: Apotex Inc.; listing date 2014-03-27 Health Canada: Cancelled post market since 2025-04-17 · brand APO-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 40 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90469 · Verify on the e-Formulary ↗ (DIN 02420082)

Source record
DIN 02420082: Apo-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800237; group id 352; item number 0812; lccId None; manufacturer id APX Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02420082 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90469
Interchangeable products
Ach-Telmisartan · DIN 02407485 · $0.2161 Auro-Telmisartan · DIN 02453568 · $0.2161 Jamp Telmisartan · DIN 02386755 · $0.2161 Micardis · DIN 02240769 · $0.2161 Mint-Telmisartan · DIN 02486369 · $0.2161 NRA-Telmisartan · DIN 02503794 · $0.2161 PMS-Telmisartan · DIN 02499622 · $0.2161 Sandoz Telmisartan · DIN 02375958 · $0.2161 Telmisartan · DIN 02388944 · $0.2161 Telmisartan · DIN 02390345 · $0.2161 Teva-Telmisartan · DIN 02320177 · $0.2161
Shortage status: discontinued (2018-06-07, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02420082
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.

Apo-Telmisartan · DIN 02420090 · 80mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued 2025-04-17 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Telmisartan · DIN 02420090 Manufacturer: Apotex Inc.; listing date 2014-03-27 Health Canada: Cancelled post market since 2025-04-17 · brand APO-TELMISARTAN · ATC C09CA07 TELMISARTAN · form Tablet · route Oral · ingredients TELMISARTAN 80 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Telmisartan: Formulary list price $0.2161/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2161 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90470 · Verify on the e-Formulary ↗ (DIN 02420090)

Source record
DIN 02420090: Apo-Telmisartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800238; group id 352; item number 0813; lccId None; manufacturer id APX Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2161; ministry $0.2161 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02420090 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90470
Interchangeable products
Ach-Telmisartan · DIN 02407493 · $0.2161 Auro-Telmisartan · DIN 02453576 · $0.2161 Co Telmisartan · DIN 02393255 · $0.2161 Jamp Telmisartan · DIN 02386763 · $0.2161 Micardis · DIN 02240770 · $0.2161 Mint-Telmisartan · DIN 02486377 · $0.2161 NRA-Telmisartan · DIN 02503808 · $0.2161 PMS-Telmisartan · DIN 02499630 · $0.2161 Sandoz Telmisartan · DIN 02375966 · $0.2161 Telmisartan · DIN 02388952 · $0.2161 Telmisartan · DIN 02390353 · $0.2161 Teva-Telmisartan · DIN 02320185 · $0.2161
Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02420090
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

IRBESARTAN

· 41 products · Listed, not a benefit (1), General benefit (40) · strengths: 75mg, 150mg, 300mg · Tab

LOSARTAN POTASSIUM

· 42 products · General benefit · strengths: 25mg, 50mg, 100mg · Tab

OLMESARTAN MEDOXOMIL

· 22 products · General benefit · strengths: 20mg, 40mg · Tab

VALSARTAN

· 38 products · Off-Formulary Interchangeable, not an ODB benefit (10), General benefit (28) · strengths: 40mg, 80mg, 160mg, 320mg · Tab

EPROSARTAN MESYLATE

· 2 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada · strengths: 400mg, 600mg · Tab

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

CILAZAPRIL & HYDROCHLOROTHIAZIDE

· 2 products · General benefit · strengths: 5mg/12.5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 33 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10 Product monograph and 19 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Treatment of Essential Hypertension MICARDIS (telmisartan) is indicated for the treatment of mild to moderate essential hypertension in adults. MICARDIS may be used alone or in combination with thiazide diuretics. The concurrent use with angiotensin converting enzyme inhibitors is not recommended. Risk Reduction of Cardiovascular Morbidity MICARDIS is indicated to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in adults 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme inhibitor (ACEI). High risk of cardiovascular events includes evidence of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or diabetes mellitus with evidence of end- organ damage. MICARDIS has been used with other required treatment such as other antihypertensives (including ACEI), antiplatelet or statins (see 7 WARNINGS AND PRECAUTIONS, 9 DRUG INTERACTIONS and 14 CLINICAL TRIALS section). 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of MICARDIS in pediatric patients has not be… https://pdf.hres.ca/dpd_pm/00067655.PDF PM date: SEP 01, 1999 Source product: MICARDIS 40MG TAB; DIN 02240769; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS TWYNSTA (telmisartan/amlodipine besylate) is indicated for: • treatment of mild to moderate essential hypertension for whom combination therapy with telmisartan and amlodipine is appropriate. TWYNSTA is not indicated for initial therapy (see 4 DOSAGE AND ADMINISTRATION). 1.1 Pediatrics • Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of TWYNSTA in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics • Geriatrics (> 65 years of age): No dose adjustment is necessary for geriatric patients. It should be recognized, however, that greater sensitivity in some older individuals cannot be ruled out. https://pdf.hres.ca/dpd_pm/00077924.PDF PM date: AUG 11, 2011 Source product: TWYNSTA; DIN 02371022; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS MICARDIS PLUS (80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated for: • treatment of mild to moderate essential hypertension in patients in whom combination therapy with telmisartan and hydrochlorothiazide is considered appropriate. MICARDIS PLUS (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated for: • treatment of patients whose blood pressure is not adequately controlled by MICARDIS PLUS 80 mg/12.5 mg or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. These fixed-dose combinations are not indicated as initial therapy (see 4 DOSAGE AND ADMINISTRATION). 1.1 Pediatrics • Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of MICARDIS PLUS in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics • Geriatrics (> 65 years of age): No dosage adjustment is necessary. It should be recognized, however, that greater sensitivity in some older individual… https://pdf.hres.ca/dpd_pm/00077923.PDF PM date: NOV 28, 2024 Source product: MICARDIS PLUS; DIN 02244344; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Telmisartan · DIN 02320177 Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02320177

Check this DIN again

Teva-Telmisartan · DIN 02320185 Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02320185

Check this DIN again

Apo-Telmisartan · DIN 02420082 Shortage status: discontinued (2018-06-07, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02420082

Check this DIN again

Apo-Telmisartan · DIN 02420090 Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02420090

Check this DIN again